<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d139" origId="Deferasirox"><sentence id="DrugDDI.d139.s0" origId="s0" text="The concomitant administration of Exjade and aluminum-containing antacid preparations has not been formally studied."><entity id="DrugDDI.d139.s0.e0" origId="s0.p1" charOffset="34-40" type="drug" text="Exjade"/><entity id="DrugDDI.d139.s0.e1" origId="s0.p3" charOffset="45-85" type="drug" text="aluminum-containing antacid preparations"/><pair id="DrugDDI.d139.s0.p0" e1="DrugDDI.d139.s0.e0" e2="DrugDDI.d139.s0.e1" interaction="false"/></sentence><sentence id="DrugDDI.d139.s1" origId="s1" text="Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations."><entity id="DrugDDI.d139.s1.e0" origId="s1.p10" charOffset="9-20" type="drug" text="deferasirox"/><entity id="DrugDDI.d139.s1.e1" origId="s1.p15" charOffset="64-68" type="drug" text="iron"/><entity id="DrugDDI.d139.s1.e2" origId="s1.p16" charOffset="70-76" type="drug" text="Exjade"/><entity id="DrugDDI.d139.s1.e3" origId="s1.p21" charOffset="102-142" type="drug" text="aluminum-containing antacid preparations"/><pair id="DrugDDI.d139.s1.p0" e1="DrugDDI.d139.s1.e0" e2="DrugDDI.d139.s1.e1" interaction="false"/><pair id="DrugDDI.d139.s1.p1" e1="DrugDDI.d139.s1.e0" e2="DrugDDI.d139.s1.e2" interaction="false"/><pair id="DrugDDI.d139.s1.p2" e1="DrugDDI.d139.s1.e0" e2="DrugDDI.d139.s1.e3" interaction="false"/><pair id="DrugDDI.d139.s1.p3" e1="DrugDDI.d139.s1.e1" e2="DrugDDI.d139.s1.e2" interaction="false"/><pair id="DrugDDI.d139.s1.p4" e1="DrugDDI.d139.s1.e1" e2="DrugDDI.d139.s1.e3" interaction="false"/><pair id="DrugDDI.d139.s1.p5" e1="DrugDDI.d139.s1.e2" e2="DrugDDI.d139.s1.e3" interaction="false"/></sentence><sentence id="DrugDDI.d139.s2" origId="s2" text="In healthy volunteers, Exjade had no effect on the pharmacokinetics of digoxin."><entity id="DrugDDI.d139.s2.e0" origId="s2.p23" charOffset="23-29" type="drug" text="Exjade"/><entity id="DrugDDI.d139.s2.e1" origId="s2.p27" charOffset="71-78" type="drug" text="digoxin"/><pair id="DrugDDI.d139.s2.p0" e1="DrugDDI.d139.s2.e0" e2="DrugDDI.d139.s2.e1" interaction="false"/></sentence><sentence id="DrugDDI.d139.s3" origId="s3" text="The effect of digoxin on Exjade pharmacokinetics has not been studied."><entity id="DrugDDI.d139.s3.e0" origId="s3.p29" charOffset="14-21" type="drug" text="digoxin"/><entity id="DrugDDI.d139.s3.e1" origId="s3.p30" charOffset="25-31" type="drug" text="Exjade"/><pair id="DrugDDI.d139.s3.p0" e1="DrugDDI.d139.s3.e0" e2="DrugDDI.d139.s3.e1" interaction="false"/></sentence><sentence id="DrugDDI.d139.s4" origId="s4" text="The concomitant administration of Exjade and vitamin C has not been formally studied."><entity id="DrugDDI.d139.s4.e0" origId="s4.p36" charOffset="34-40" type="drug" text="Exjade"/><entity id="DrugDDI.d139.s4.e1" origId="s4.p38" charOffset="45-54" type="drug" text="vitamin C"/><pair id="DrugDDI.d139.s4.p0" e1="DrugDDI.d139.s4.e0" e2="DrugDDI.d139.s4.e1" interaction="false"/></sentence><sentence id="DrugDDI.d139.s5" origId="s5" text="Doses of vitamin C up to 200 mg were allowed in clinical studies without negative consequences."><entity id="DrugDDI.d139.s5.e0" origId="s5.p45" charOffset="9-18" type="drug" text="vitamin C"/></sentence><sentence id="DrugDDI.d139.s6" origId="s6" text="The interaction of Exjade with hydroxyurea has not been formally studied."><entity id="DrugDDI.d139.s6.e0" origId="s6.p52" charOffset="19-25" type="drug" text="Exjade"/><entity id="DrugDDI.d139.s6.e1" origId="s6.p53" charOffset="31-42" type="drug" text="hydroxyurea"/><pair id="DrugDDI.d139.s6.p0" e1="DrugDDI.d139.s6.e0" e2="DrugDDI.d139.s6.e1" interaction="false"/></sentence><sentence id="DrugDDI.d139.s7" origId="s7" text="No inhibition of deferasirox metabolism by hydroxyurea is expected based on the results of an in vitro study."><entity id="DrugDDI.d139.s7.e0" origId="s7.p60" charOffset="17-28" type="drug" text="deferasirox"/><entity id="DrugDDI.d139.s7.e1" origId="s7.p61" charOffset="43-54" type="drug" text="hydroxyurea"/><pair id="DrugDDI.d139.s7.p0" e1="DrugDDI.d139.s7.e0" e2="DrugDDI.d139.s7.e1" interaction="false"/></sentence><sentence id="DrugDDI.d139.s8" origId="s8" text="Exjade should not be combined with other iron chelator therapies, as safety of such combinations has not been established."><entity id="DrugDDI.d139.s8.e0" origId="s8.p67" charOffset="0-6" type="drug" text="Exjade"/><entity id="DrugDDI.d139.s8.e1" origId="s8.p72" charOffset="41-65" type="drug" text="iron chelator therapies"/><pair id="DrugDDI.d139.s8.p0" e1="DrugDDI.d139.s8.e0" e2="DrugDDI.d139.s8.e1" interaction="false"/></sentence><sentence id="DrugDDI.d139.s9" origId="s9" text="Drug/Food Interactions The bioavailability (AUC) of deferasirox was variably increased when taken with a meal."><entity id="DrugDDI.d139.s9.e0" origId="s9.p80" charOffset="0-4" type="drug" text="Drug"/><entity id="DrugDDI.d139.s9.e1" origId="s9.p85" charOffset="52-63" type="drug" text="deferasirox"/><pair id="DrugDDI.d139.s9.p0" e1="DrugDDI.d139.s9.e0" e2="DrugDDI.d139.s9.e1" interaction="false"/></sentence><sentence id="DrugDDI.d139.s10" origId="s10" text="Deferasirox should be taken on an empty stomach 30 minutes before eating."><entity id="DrugDDI.d139.s10.e0" origId="s10.p92" charOffset="0-11" type="drug" text="Deferasirox"/></sentence><sentence id="DrugDDI.d139.s11" origId="s11" text="Exjade tablets for oral suspension can be dispersed in water, orange juice, or apple juice."><entity id="DrugDDI.d139.s11.e0" origId="s11.p98" charOffset="0-6" type="drug" text="Exjade"/><entity id="DrugDDI.d139.s11.e1" origId="s11.p103" charOffset="55-60" type="drug" text="water"/><pair id="DrugDDI.d139.s11.p0" e1="DrugDDI.d139.s11.e0" e2="DrugDDI.d139.s11.e1" interaction="false"/></sentence></document>